The metabolism of hypertriglyceridemic low density lipoprotein (HTG-LDL) was investigated in upregulated cultured human skin fibroblasts. Low density lipoprotein (LDL) was isolated by zonal centrifugation from the plasma of seven HTG subjects, before and 2 wk after the initiation of bezafibrate (BZ) therapy. HTG-LDL is a cholesterol-poor, triglyceride-rich lipoprotein of smaller diameter than BZ-LDL or normal LDL (N-LDL). Binding, cell association, and proteolytic degradation of HTG-LDL were compared with that of BZ-LDL and N-LDL and were found to be significantly lower by a paired t test analysis (P < 0.001). After 6 h preincubation with unlabeled HTG-LDL, the incorporation of [14Clacetate to sterols was significantly higher than with BZ-LDL or N-LDL (577±43.7; 330±41.5; 262±47, mean±SE, picomoles sterols per milligram cell protein per 2 h, respectively; P < 0.001 by paired t test).
Introduction
Several abnormalities have been consistently observed in lipoproteins isolated from the plasma of hypertriglyceridemic (HTG)' human subjects. Very low density lipoprotein (VLDL) 1 . Abbreviations used in this paper: apo, apoprotein; BZ, bezafibrate; FCS, fetal calf serum; HTG, hypertriglyceridemic; LPDS, lipoprotein deficient serum; N-LDL, normal low density lipoprotein.
is cholesteryl ester-rich and free cholesterol-rich and proteinpoor (1, 2) ; low density lipoprotein (LDL) appears as multiple populations (1, 3) , is protein-rich and triglyceride-rich, and contains considerably less free and esterified cholesterol than normal LDL (1, 2, (4) (5) (6) . HTG-LDL is also smaller and denser than normal LDL (1, 2) . HTG-high density lipoprotein (HDL) belongs predominantly to the HDL3 subpopulation (1, 7), and like LDL, is relatively enriched with protein and triglyceride and contains less cholesteryl ester molecules than normal HDL3 (1, 6, 8, 9) . These compositional changes are strongly related to the plasma triglyceride levels and many if not all revert toward normal when hypolipidemic therapy is instituted (1) .
It has been suggested that most of the abnormalities in HTG lipoproteins reflect an enhanced activity of the lipidtransfer reaction (1, 6, 8, 9) , mediated by specific proteins present in plasma of human and some animal species (10-16). According to this view, the presence of a high concentration of triglyceride-rich lipoproteins in the plasma induces accelerated transfer of cholesteryl ester from LDL and HDL to VLDL and chylomicrons and of triglyceride in the opposite direction. Thus, cholesteryl ester and triglyceride redistribution seem to be an integral feature of the lipoprotein system in hypertriglyceridemia.
Lipoprotein cholesterol is an important regulator of cellular metabolic events (17, 18) . Therefore, we considered the possibility that the altered composition of LDL found in HTG states may change the interaction between this lipoprotein and peripheral cells. We would expect also that correction of the compositional change of LDL would result in normalization of lipoprotein cell interaction. To test this hypothesis, we have studied the receptor mediated metabolism of LDL by cultured human skin fibroblasts exposed to HTG-LDL isolated before and 2 wk after initiation of bezafibrate (BZ) therapy. The results obtained demonstrate that HTG-LDL is less effective in down-regulation of the LDL receptor activity and inhibition of sterol synthesis by the cells. Normalization of this defect was found with therapy. Methods the following protocol: the first sample, A, was drawn while the subjects received BZ; on that day, therapy was discontinued, and 2 wk later, a second sample, B, was drawn and BZ was reinstituted. 2 wk later, a third sample, C, was obtained. LDL was isolated, characterized, and assayed in normal human skin fibroblasts for binding, cell association, proteolytic degradation, and ["C]acetate incorporation into sterol. In each experiment, HTG and BZ-LDL were examined together with a control normal LDL (N-LDL) isolated from the normotriglyceridemic subjects.
Isolation and characterization ofLDL. Blood was drawn into tubes containing EDTA (I mg/ml). Zonal ultracentrifugation was employed to isolate LDL from the hyperlipidemic subjects according to the method published by Patsch et al. (20) . This procedure was suitable to separate LDL of abnormal composition, size, and density (1). Zonal ultracentrifugation was performed in a Ti-14 zonal rotor. A NaBr gradient of 1.0-1.3 g/ml was established with the help of a high capacity gradient pump (141; Beckman Instruments, Inc., Fullerton, CA). The rotor was loaded with a plasma fraction of d 1.006-1.085 g/ml (isolated from 80-140 ml plasma) and the LDL was eluted after 140 min centrifugation at 42,000 rpm. The eluate was monitored continuously at 280 nm by a multiwavelength absorbance monitor (Model UA-5; Isco, Inc., Lincoln, NE). The main LDL fraction (1) was isolated and used in tissue culture experiments. N-LDL was isolated by preparative ultracentrifugation at d = 1.019-1.063 g/ml, and lipoprotein deficient plasma was isolated from normal subjects at d > 1.25 g/ml in fixed angle rotors (SOTi, 6OTi) using an ultracentrifuge (L5-50B; Beckman Instruments, Inc.). The LDL was dialyzed against 0.15 M NaCl, 1 mM EDTA solution. The zonal LDL was concentrated by vacuum ultrafiltration. All preparations were sterilized by passage through a 0.45-Am millipore filter. Electron microscopy was used to determine the size of lipoproteins. Electron micrographs were obtained using an electron microscope (300; Philips Electronic Instruments, Inc., Mahwah, NJ) as described previously (1) . Triglycerides were determined according to the U. S. Lipid Research Clinics protocol using an AutoAnalyzer AAII (Technicon Corp., Tarrytown, NY) (21) . Cholesteryl ester and free cholesterol content in lipoproteins were determined enzymatically (22) with a commercial kit (Boehringer Mannheim GmbH Diagnostics, Mannheim, West Germany). Radioactive sterols were isolated by thin layer chromatography on silica gel plates using the solvent system petroleum ether/diethyl ether/acetic acid, 80:20:1 (vol/vol/vol) (23) . Phospholipids were determined by the Bartlett procedure (24) . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of apolipoproteins on 10% gels was performed after the methods described by Weber and Osborn (25) . LDL protein was measured by the method of Lowry et al. (26) using bovine serum albumin (BSA) as a standard.
Iodination of LDL. '251-labeled LDL was prepared by the iodine monochloride method of MacFarlane (27) Assays of binding, cell association, and proteolytic degradation of "'I-LDL. On the day of experiment, the serum containing medium was removed, the cell layer was washed with PBS, and the cells were incubated with '25I-LDL, 15 Mg protein/ml, in lipoprotein deficient medium at 370C. After 6 h of incubation, the medium was examined for noniodide '25I-LDL degradation products according to (31) . The cells were then washed and dissolved in 1 ml of0.5 N NaOH. Cell associated LDL was determined as '251I-LDL radioactivity in the dissolved cells; cell protein was determined subsequently by the method of Lowry et al. (26) . Cell associated LDL represents the radioactivity recovered in the cells after the incubation with heparin.
Incorporation of["CC]acetate to sterols. To determine the ability of LDL to regulate sterol synthesis, fibroblasts were incubated with unlabeled HTG-LDL or BZ-LDL, 15 Mg protein in 1 ml LPDS medium. After 6 h, the medium was removed and the cells were washed extensively with PBS + 0.2% BSA. 1 ml of serum free medium containing 10 MCi of 2["4C]acetate was added and incubation continued at 370C for 2 h. The incorporation of labeled acetate into sterols was measured according to the method of Oram et al. (32) . At the end of incubation, the medium was removed and the cells were washed three times with PBS. The lipids were extracted by the addition of hexane/ isopropanol (3:2, vol/vol), for 1 h at room temperature, followed by two rapid similar extractions. The pooled solvents were evaporated to dryness, the cholesteryl ester was hydrolyzed with I N KOH in 95% ethanol for 1 h at 85°C, and the sterols were re-extracted into 2 ml hexane. A 0.5-ml hexane aliquot was counted in a beta scintillation spectrometer. The [14Cjsterol fraction was determined by thin layer chromatography on silica gel G plates, using petroleum ether/diethyl ether/acetic acid (80:20:1, vol/vol/vol) as the developing solvent. Usually, >80% of the hexane extracted radioactivity was found in the sterol fraction. Incorporation of [14C]acetate to sterols is expressed as picomoles of acetate found in the sterol fraction (calculated from the specific activity of the acetate (55 mCi/mmol)).
Effect of a prolonged exposure to unlabeled LDL. Upregulated cells were preincubated for 48 h with HTG-LDL and BZ-LDL, at concentrations of 15 Mg protein/ml. After the preincubation period, the medium was removed and`25I-LDL obtained from normal donors (N-LDL; 15 Mg protein/ml) in I ml medium was added and incubated with the cells for 3 h. The binding, cell association, and proteolytic degradation of '25I-N-LDL and the incorporation of [ (33) .
Results
Plasma and lipoprotein lipids. The patients' plasma lipid levels before and after 2 wk of BZ therapy are shown in Table I . The binding of N-LDL included in the same experiments was (mean±SEM, P < 0.001).
80.0±4.5. A similar trend was found for cell associated LDL HTG-LDL and BZ-LDL were separated on a zonal ultra- (Fig. 1 B) . Degradation of LDL after 6 h of incubation was centrifugation system (1) . As Binding, cell association, and proteolytic degradation. (Fig. I D) . After incubation for 6 h at 370C, the amounts of '25I-LDL bound to the cells and of noniodide '251I-N-LDL degradation products was determined as described in Methods.
Effect of increasing concentrations of HTG-LDL and N-LDL on the relationships between proteolytic degradation, cholesterol influx, and incorporation of ["C]acetate to sterols.
To assess the role of LDL composition on sterol synthesis, fibroblasts were incubated for 6 h with increasing amounts of 251I-LDL (2.5-30 gg protein). Proteolytic degradation of the '25I-LDL and incorporation of ['4C]acetate to sterols were determined as described in Methods. Cholesterol influx was calculated from the proteolytic degradation data and the total cholesterol to protein ratios of LDL. A reciprocal plot of the data is shown in Fig. 4 . At all LDL concentrations, more ['4C]acetate was incorporated to sterols with HTG-LDL when the data were correlated to proteolytic degradation (Fig. 4 A) . However, when ['4C]acetate incorporation to sterol was related to the amount of cholesterol that entered the cells, no differences were found between HTG-LDL and N-LDL (Fig. 4 B) (Fig. 6 ).
Discussion
The aim of this investigation was to determine whether LDL from HTG patients, which is known to be abnormal in structure and composition (1) (2) (3) (4) (5) (6) (7) (8) Reduced cellular binding of LDL isolated from uncontrolled type I diabetic patients (34) and from patients with diabetes with hypertriglyceridemia (35) has been reported. In a second study, binding of LDL isolated from diabetics with normal plasma triglyceride levels was found to be normal (35) . In the present investigation, we observed decreased binding by the cells of LDL obtained from patients with hypertriglyceridemia but with no diabetes. We also found that LDL binding increased when plasma triglyceride levels were reduced by BZ therapy. The defective binding was due to lower affinity of HTG-LDL for binding by the LDL receptor and seemed to reflect the degree of triglyceridemia. At the end of 6 h incubation, when LDL receptor activity is not expected to be appreciably down-regulated (36), both cell association and proteolytic degradation of HTG-LDL were markedly reduced. These parameters also reverted to normal with BZ therapy. We suggest that the defective binding of HTG-LDL by the cells is responsible for decreased entry of the LDL to the cells and to its decreased proteolytic degradation. The reason for the reduced binding and degradation of HTG-LDL is not clear. In our study, several possibilities could be ruled out.
The reversal of the binding defect with treatment indicates that the defect is not related to the genetic nature of the dyslipoproteinemic state. Apo C has been reported to inhibit degradation of chylomicron remnants by the perfused rat liver (37) , while apo E present in HTG-VLDL modulates VLDL binding by the LDL cellular receptors (38, 39) . These apoproteins were not detected in the LDL preparations used presently. The reversible compositional abnormalities of the LDL could provide one possible explanation for the defective binding. However, when the correlation between the change in cholesteryl ester/protein ratio of HTG-LDL and its reduced degradation by the cultured cells was sought, it was found to be relatively low (r = 0.66). We therefore favor another possibility, namely, that the smaller size of HTG-LDL induces conformational changes of apo B and decreases its binding to the receptors. That possibility is being investigated.
Decreased ability of LDL to suppress sterol synthesis in upregulated human skin fibroblasts has previously been shown in LDL depleted of cholesteryl esters either by reconstitution techniques or by the lipid transfer protein reaction in vitro (40, 41 (46) . In other studies, total body cholesterol synthesis was reported to be considerably higher in patients with hypertriglyceridemia as compared with normals and patients with hypercholesterolemia (47) (48) (49) (50) . The increased fractional catabolic rate of LDL-apo B could be related to the presently described finding that the HTG-LDL particle delivers less cholesterol to cells than N-LDL and therefore is less effective in the down regulation of the LDL receptor and in inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. The resulting higher activity of this enzyme would account for the increase in cholesterol synthesis in hypertriglyceridemia. Our data predict that when plasma triglyceride levels are reduced, both abnormalities should be corrected and indeed reduction in cholesterol synthesis has been reported in HTG patients treated with clofibrate (48, 49) .
